Navigation Links
Hepatitis C treatment reduces the virus but liver damage continues
Date:12/9/2008

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in the Dec. 4 issue of the New England Journal of Medicine. HALT-C was funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.

"The results from HALT- C show without question that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C in the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These findings heighten the incentive to develop more effective drugs for patients with severe liver disease due to hepatitis C."

Peginterferon therapy for up to 48 weeks is standard for chronic hepatitis C. But patients who do not have a sustained response to initial therapy have been given the drug over a longer time based on studies showing that this approach suppresses viral and enzyme levels, even if the virus is not completely eliminated. However, it was not known if long-term therapy would improve important clinical outcomes such as liver damage and death.

HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, tested whether long-term treatment with peginterferon alfa-2a would reduce the development of cirrhosis, liver cancer, or liver failure. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in wee
'/>"/>

Contact: Leslie Curtis
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
3. Stanford researchers find way to fight treacherous hepatitis B
4. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
5. Hepatitis A Vaccine Best Bet to Treat Virus
6. Hepatitis C Testing Recommended for Anyone with a Tattoo
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
10. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., Dec. 4 The following ...hysicians and Surgeons (AAPS): , ,DATE: ...,PLACE: Grand Hyatt Hotel Washington ... Renwick Room (lower level 2),EVENT: ...e, opposition to U.S. Senate he...
(Date:12/4/2009)...N and HOUSTON, Dec. 4 AE...(Nasdaq: CYBX ) announced today that Vagus Nerve... implantable medical device for the treatment of r...ations at the American Epilepsy Society,s (AES) A...ynes Convention Center in Boston, Massachusetts. ...
(Date:12/4/2009)... North American Seminars Inc. is now accepting med...al education courses at their medical facility in ...ts operation and capabilities to the medical commu...ate their physical therapy and occupational therap...over 250 live training events. , ...
(Date:12/4/2009)... Best-Selling author and Personal & Organizati...al Transformation through Accountability! , ...er 4, 2009 -- IMPAQ Accountability Business Cons..., best-selling Author, renowned Speaker, and CEO &...ultants Inc., will present at the 14th Internation...
(Date:12/3/2009)..., Dec. 3 The American R...International Brotherhood of Teamsters, Local 929 ...leaving the facility, interfering with blood shipm....newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) ...nst the American Red Cross Blood Services Penn-Jer...
Breaking Medicine News(10 mins):Health News:State Legislators in D.C. To Blast Senate Healthcare Bill at News Conference; Say Tramples States' Rights, and Saddles with Massive Medicaid Bills; Push Bills to Block Federal Mandates 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:American Red Cross Wins Court Injunction Against Striking Teamsters 2
...an., June 5 Fort Dodge Animal Health, a,division ...oduction of,ProHeart(R) 6, a unique heartworm prev...uncement follows a review by the U.S. Food and Dru...on,to return this life-saving product to the marke...
...Spot for the World,s Longest Indoor Stair Climb Be...on, CHICAGO, June 5 Registration for Go Vertical...o the top of the Sears,Tower, opens at 9 a.m. CDT ... is limited to the first 2,250 registrants, and wi...
... it possible to restore function to a paralyzed li...s disease? These are two of the several topics th...erence, June 16-18, hosted by Case Western Reserve...lready provided substantive benefits to many indiv...
... Three-Year Plan -, SAN ANTONIO, June 5 American...American Heartworm Society president, Dr.,Sheldon ... conduct the most,comprehensive heartworm incidenc...e through corporate sponsorship, will be,distribut...
...ely to smoke, abuse drugs, alcohol, study finds , ...ns with bipolar disorder are at greater risk of s...eneral Hospital (MGH) study that supports previous...uvenile delinquency," study leader Dr. Timothy Wil...
...cs effects of caloric restriction to extend life s...ay News) -- Resveratrol, a compound found in grape... may protect the heart and slow the effects of agi... percent fewer calories than a typical diet that h...
Other Medicine News:Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 2Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 4Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 5Health News:Go Vertical Chicago 2008 Sears Tower Stair Climb Registration Opens June 10 2Health News:Go Vertical Chicago 2008 Sears Tower Stair Climb Registration Opens June 10 3Health News:Premier conference on neurotechnology and deep brain stimulation to be held in Cleveland June 16-18 2Health News:American Heartworm Society Announces Heartworm Incidence Survey 2Health News:Bipolar Teens at Greater Risk of Substance Abuse 2Health News:Red Wine Compound Helps Heart, May Slow Aging 2
(Date:12/3/2009)... WALTHAM, Mass., Dec. 3 Decision...d advisory firms focusing on pharmaceutical and he...s drug market in Brazil will grow from $417 millio...5 percent annual growth rate is attributed to a gr...ased use of new generation antidiabetics such as M...
(Date:12/3/2009)...S ANGELES, Dec. 3 Instac...ovider of life-saving prescription drugs, home tes...ulfillment provider of direct to patient diabetes ...hnology and revolutionary cell phone centric techn... file multiple updated and enhanced patent and tra...
(Date:12/3/2009)...IEGO, Dec. 3 Amira Pharmaceutica...m a Phase 1 clinical study of AM461, the Company,s... known as CRTH2) receptor. ,, The interim res...dynamic (PD) effect can be achieved with AM461. A...es a good safety profile. AM461 is a back-up to A...
Breaking Medicine Technology:Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products 2Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2MedNet Solutions Named to the Inc 5000 List Three Years in a Row 54901 1MedNet Solutions Named to the Inc 5000 List Three Years in a Row 54901 2Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 1Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 2Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 3Treatment May Limit Graft Versus Host Disease 54894 1Treatment May Limit Graft Versus Host Disease 54894 2
... in Stable Asthma and Exercise-Induced ...ING, Pa., March 18 Genaera,Corporation (Nasdaq: ...Immune, has initiated its fourth phase 2a clinical...dy (MAb) targeting interleukin-9 (IL-9), in,patien... assess the,potential of MEDI-528 in patients with...
...icromet, Inc.,(Nasdaq: MITI ), a biopharmaceutica... for the treatment of cancer, inflammation and aut... be presented on April 14, 2008,at the annual meet...ACR) to,be held at the San Diego Convention Center...gress on the company,s proprietary BiTE(R) antibod...
Other Medicine Technology:Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 2Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 3Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 4Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research 2Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research 3Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research 4Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research 5
...ghly effective surgical alternative for the treatm...s positioned close to the high pressure zone of th...ree support of the urethra in the correct position...es, with minimal tissue dissection. Clinical studi...
...s, the PeaceKeeper 20 gauge multi-modality intraoc...Field comprehensive family of lightweight Eraser b... Combining highly effective bipolar hemostasis wit... in a single use, sterile instrument, the PeaceKee...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
SUR-FIT Natura® Urostomy Pouch
Medicine Products: